Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

169
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
169
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

198
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
198

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Defining quality standards of care in CTD-PAH and management best practices: a Delphi panel consensus.

Rheumatology advances in practice·2026
Same author

Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers.

Scientific reports·2026
Same author

Pulmonary Veno-Occlusive Disease in a Military Pilot: Case Report and Mini-Review.

Current cardiology reviews·2026
Same author

Adaptation of ACMG/AMP Guidelines for Clinical Classification of <i>BMPR2</i> Variants in Pulmonary Arterial Hypertension Resolves Variants of Unclear Pathogenicity in ClinVar.

Human mutation·2025
Same author

Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertension.

NPJ genomic medicine·2025
Same author

Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial.

Advances in therapy·2025

相关实验视频

Updated: Jun 25, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

[可以遗传的肺动脉高血压]

Christina A Eichstaedt1,2, Memoona Shaukat3,4, Ekkehard Grünig3

  • 1Zentrum für Pulmonale Hypertonie, Thoraxklinik am Universitätsklinikum Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Deutschland. christina.eichstaedt@med.uni-heidelberg.de.

Innere Medizin (Heidelberg, Germany)
|May 21, 2024
PubMed
概括

基因检测确定了超过18个导致遗传性肺动脉高血压 (PAH) 的基因,其中BMPR2是最常见的. 这有助于诊断和家庭查,并且正在出现针对BMPR2途径的新疗法.

关键词:
骨形态遗传蛋白受体2 (BMPR2) 是一种骨形态遗传蛋白受体.基因检测是一种基因检测.肺高血压是因为肺高血压.肺部静脉封闭性疾病 肺部静脉封闭性疾病减少了透率的减少.这就是Sotatercept.

更多相关视频

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K

相关实验视频

Last Updated: Jun 25, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.3K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K

科学领域:

  • 遗传学 是一个遗传学.
  • 心脏病学 心脏病学
  • 肺部病理学 肺部病理学

背景情况:

  • 遗传性肺动脉高血压 (PAH) 是一种严重的疾病,与遗传突变有关.
  • 涉及超过18个基因,其中骨形态遗传蛋白受体2 (BMPR2) 是最常发生变化的.
  • 同一个信号通路内的相关基因的突变也会导致PAH的发展.

研究的目的:

  • 审查遗传性PAH的遗传基础.
  • 突出基因检测在诊断PAH和相关疾病中的作用.
  • 讨论遗传发现对家庭成员和新兴治疗策略的影响.

主要方法:

  • 在PAH中遗传因素的文献综述.
  • 分析基因测试对差异诊断的有用性.
  • 遗传模式和新型治疗方法的概述.

主要成果:

  • 确定了至少18个与遗传性PAH相关的基因,其中BMPR2突变是最常见的.
  • 证实了基因检测对诊断PAH和区分它与肺静脉闭塞疾病的有用性.
  • 突出了基因测试的潜力,以促进风险家庭的级联查.

结论:

  • 基因检测对于诊断遗传性PAH和指导家庭查至关重要.
  • 了解基因基础,特别是BMPR2通路的改变,是开发向疗法的关键.
  • 新兴的治疗方法旨在重新平衡BMPR2信号通路,为PAH患者提供新的希望.